Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02404493 · ClinicalTrials.gov registry record · NA
Test to Determine the Effectiveness of Moisturizing Balm Used on Babies With Dry, Itchy Skin
A NA study, sponsored by Johnson & Johnson Consumer Inc. (J&JCI).
- Terminated
- Registry status
- NA
- Development phase
- 23
- Enrollment target
NCT02404493: Clinical Trial NA study, sponsored by Johnson & Johnson Consumer Inc. (J&JCI).
NCT02404493 is a NA study that was terminated before completion, run by Johnson & Johnson Consumer Inc. (J&JCI). The registered enrollment target is 23 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02404493, a NA study, was terminated before completion, sponsored by Johnson & Johnson Consumer Inc. (J&JCI).
- TERMINATED
- Registry status
- NA
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this 3 week study is to test the effectiveness of an over-the-counter (OTC) skin balm in infants and toddlers with mild to moderate dry, itchy skin.
Primary Outcome
Corneometer is a non-invasive instrument that measures hydration on the skin surface. During assessment, the corneometer was placed at a site adjacent to affected skin areas. Corneometer readings are directly related to the skin's electrical capacitance and increase as the skin becomes more hydrated.
Interventions
- DEVICE EpiCeram Skin Barrier Emulsion
- DRUG 1% Colloidal Oatmeal Balm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2015-03 |
| Est. Completion | 2016-03 |
| Phase | NA |
Why NCT02404493 stopped before completion
NCT02404493 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which EpiCeram Skin Barrier Emulsion is the first listed.
NCT02404493 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02404493 about?
NCT02404493 is a clinical study titled "Test to Determine the Effectiveness of Moisturizing Balm Used on Babies With Dry, Itchy Skin". The purpose of this 3 week study is to test the effectiveness of an over-the-counter (OTC) skin balm in infants and toddlers with mild to moderate dry, itchy skin.
What is the current status of trial NCT02404493?
This trial is currently terminated. It is a NA study. The enrollment target is 23 participants. The study started on 2015-03. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02404493?
The interventions under investigation include: EpiCeram Skin Barrier Emulsion (DEVICE), 1% Colloidal Oatmeal Balm (DRUG).
Who is sponsoring clinical trial NCT02404493?
This trial is sponsored by Johnson & Johnson Consumer Inc. (J&JCI), which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02404493's enrollment target sits among peer trials
23 1755th of 2000 higher than 245 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia